Is Aldeyra Therapeutics Inc’s (NASDAQ: ALDX) Stock Ready For A Price Spike?

NOVA

In the last trading session, 1.11 million shares of the Aldeyra Therapeutics Inc (NASDAQ:ALDX) were traded, and its beta was 0.77. Most recently the company’s share price was $2.70, and it changed around -$0.11 or -3.91% from the last close, which brings the market valuation of the company to $161.72M. ALDX currently trades at a discount to its 52-week high of $7.20, offering almost -166.67% off that amount. The share price’s 52-week low was $1.14, which indicates that the current value has risen by an impressive 57.78% since then.

Aldeyra Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended ALDX as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight.

Aldeyra Therapeutics Inc (NASDAQ:ALDX) trade information

Instantly ALDX has showed a red trend with a performance of -3.91% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.89 on recent trading dayincreased the stock’s daily price by 6.57%. The company’s shares are currently down -45.89% year-to-date, but still down -2.17% over the last five days. On the other hand, Aldeyra Therapeutics Inc (NASDAQ:ALDX) is 90.14% up in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $11, which translates to bulls needing to increase their stock price by 75.45% from its current value. Analyst projections state that ALDX is forecast to be at a low of $10 and a high of $12.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 15.99%. Aldeyra Therapeutics Inc earnings are expected to increase by 16.10% in 2025, but the outlook is positive 37.68% per year for the next five years.

ALDX Dividends

Aldeyra Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-27.

KNOLL CAPITAL MANAGEMENT, LLC, with 9.2158% or 5.48 million shares worth $18.12 million as of 2024-06-30, holds the second largest percentage of outstanding shares.

VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 1.76 shares worth $4.75 million, making up 2.94% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 1.32 shares worth around $3.57 million, which represents about 2.21% of the total shares outstanding.